We explored whether self-reported current cannabis use is associated with inflammatory biomarkers among people with HIV (PWH), given high rates of cannabis use and chronic immune activation among PWH.
Methods:
At seven Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort sites, which integrate data on participant characteristics including demographic and clinical information, and substance use behaviors, we used linear regression to estimate the average difference in biomarkers associated with cannabis use, adjusted for demographic characteristics and sampling weights. Cannabis use was considered as Never, Former, or Current (past 3-month) use. Thirteen plasma biomarkers were measured once on or after 2010 among a subset of PWH on antiretroviral therapy with HIV viral suppression within CNICS. Cannabis use was assessed within 1 year prior to biomarker collection. Biomarkers were log-transformed and scaled by standard deviation to standardize estimates.
Results:
Among 532 PWH, the average age at biomarker collection date was 47 years, 84% were male, 61% non-White, 30% reported current cannabis use, 35% former use, and 35% never using cannabis. In adjusted linear regression, current cannabis use was associated with higher soluble CD14 (sCD14) levels (β = 0.35; 95% confidence interval [CI]: 0.09, 0.61). Former cannabis use was associated with lower C-reactive protein (CRP) (β = −0.25; 95% CI: −0.47, −0.04), although current use was not (β = −0.25; 95% CI: −0.51, 0.01) compared to never use.
Conclusions:
Cannabis use may be related to lower CRP and elevated markers of microbial translocation (e.g., sCD14), which could have implications in increasing the risk of vascular events and should be investigated in a longitudinal setting.
TrickeyA, SabinCA, BurkholderG, et al.Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies. Lancet HIV2023;10(5):e295–e307.
2.
WandelerG, JohnsonLF, EggerM. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: Comparisons with general population. Curr Opin HIV AIDS2016;11(5):492–500.
3.
FerrucciL, FabbriE. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol2018;15(9):505–522.
4.
WebelAR, SchexnayderJ, CioePA, et al.A review of chronic comorbidities in adults living with HIV: State of the Science. J Assoc Nurses AIDS Care2021;32(3):322–346.
5.
LiX, LiC, ZhangW, et al.Inflammation and aging: Signaling pathways and intervention therapies. Signal Transduct Target Ther2023;8(1):239.
6.
PetersonTE, BakerJV. Assessing inflammation and its role in comorbidities among persons living with HIV. Curr Opin Infect Dis2019;32(1):8–15.
7.
CraneHM, NanceRM, WhitneyBM, et al.Drug and alcohol use among people living with HIV in care in the United States by geographic region. AIDS Care2021;33(12):1569–1576.
8.
ShiauS, ArpadiSM, YinMT, et al.Patterns of drug use and HIV infection among adults in a nationally representative sample. Addict Behav2017;68:39–44.
9.
Results from the 2023 National Survey on Drug Use and Health: Detailed tables. Quality CfBHSa; 2024.
10.
FredericksenR, EmmaF, MaksimS, et al.Changes in marijuana use and associated attitudes and health behaviors among patients in HIV care in the US in the post-legalization era: A qualitative study. Journal of AIDS and HIV Research2023;15(1):1–9.
11.
LaperS, HilemanCO, BlockG, et al.Perceived risks and benefits and frequency of cannabis use among people with HIV in different legal environments. AIDS Res Hum Retroviruses2024;40(5):293–300.
12.
GreenwaldMK, AkcasuN, BaalP, et al.Cannabis and complementary/alternative self-treatment approaches for symptom management among African American persons living with HIV. AIDS Care2023;35(1):78–82.
13.
LeinenZJ, MohanR, PremadasaLS, et al.Therapeutic Potential of Cannabis: A Comprehensive Review of Current and Future Applications. Biomedicines2023;11(10):2630.
14.
VolkowND, ComptonWM, WeissSR. Adverse health effects of marijuana use. N Engl J Med2014;371(9):879.
15.
ZhangX, WuLT. Marijuana use and sex with multiple partners among lesbian, gay and bisexual youth: Results from a national sample. BMC Public Health2017;17(1):19.
16.
BahjiA, LiY, Vickers-SmithR, et al.Self-reported cannabis use and HIV viral control among patients with HIV engaged in care: Results from a national cohort study. Int J Environ Res Public Health2022;19(9):5649.
17.
HartzlerB, DombrowskiJC, WilliamsJR, et al.Influence of substance use disorders on 2-year HIV care retention in the United States. AIDS Behav2018;22(3):742–751.
18.
RichardsonJD, KiloS, HargreavesKM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain1998;75(1):111–119.
19.
NagarkattiP, PandeyR, RiederSA, et al.Cannabinoids as novel anti-inflammatory drugs. Future Med Chem2009;1(7):1333–1349.
20.
FergusonEG, MannesZL, EnnisN. Is marijuana use associated with lower inflammation? Results from waves III and IV of the national longitudinal study of adolescent to adult health. Drug Alcohol Depend2019;198:162–167.
21.
MorganE, HudsonH, D’AquilaR, et al.Plasma C-reactive protein is lower among marijuana using HIV-negative individuals but not among persons living with HIV. Sci Rep2021;11(1):4816.
22.
AlshaarawyO, AnthonyJC. Cannabis smoking and serum C-reactive protein: A quantile regressions approach based on NHANES 2005-2010. Drug Alcohol Depend2015;147:203–207.
23.
GurgenciT, KijankaG, GreerR, et al.Exploring potential anti-inflammatory effects of medicinal cannabis. Support Care Cancer2023;31(12):629.
24.
ZevinAS, McKinnonL, BurgenerA, et al.Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS2016;11(2):182–190.
25.
SandlerNG, DouekDC. Microbial translocation in HIV infection: Causes, consequences and treatment opportunities. Nat Rev Microbiol2012;10(9):655–666.
26.
MacCannR, LandayAL, MallonPWG. HIV and comorbidities - the importance of gut inflammation and the kynurenine pathway. Curr Opin HIV AIDS2023;18(2):102–110.
27.
OkaforCN, SomasunderamA, LakeJE, et al.Cannabis use and biomarkers of inflammation, immune activation, and microbial translocation in persons with HIV. Cannabis Cannabinoid Res2024;9(6):e1579–e87.
28.
CastroFOF, SilvaJM, DornelesGP, et al.Distinct inflammatory profiles in HIV-infected individuals under antiretroviral therapy using cannabis, cocaine or cannabis plus cocaine. AIDS2019;33(12):1831–1842.
29.
VidotDC, ManuzakJA, KlattNR, et al.Brief report: Hazardous cannabis use and monocyte activation among methamphetamine users with treated HIV infection. J Acquir Immune Defic Syndr2019;81(3):361–364.
30.
Mboumba BouassaRS, ComeauE, AlexandrovaY, et al.Effects of oral cannabinoids on systemic inflammation and viral reservoir markers in people with HIV on antiretroviral therapy: Results of the CTN PT028 Pilot Clinical Trial. Cells2023;12(14):1811.
31.
KitahataMM, RodriguezB, HaubrichR, et al.Cohort profile: The centers for AIDS research network of integrated clinical systems. Int J Epidemiol2008;37(5):948–955.
32.
GrahamSM, NanceRM, ChenJ, et al.Plasma Interleukin-6 (IL-6), Angiopoietin-2, and C-reactive protein levels predict subsequent type 1 myocardial infarction in persons with treated HIV Infection. J Acquir Immune Defic Syndr2023;93(4):282–291.
33.
FordES, GreenwaldJH, RichtermanAG, et al.Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS2010;24(10):1509–1517.
34.
HuntPW, SinclairE, RodriguezB, et al.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis2014;210(8):1228–1238.
35.
BoulwareDR, HullsiekKH, PuronenCE, INSIGHT Study Group. et al.; Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis2011;203(11):1637–1646.
36.
SandlerNG, WandH, RoqueA, INSIGHT SMART Study Group. et al.; Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis2011;203(6):780–790.
37.
RudermanSA, HuntPW, Beck-EngeserG, et al.Biomarkers of microbial translocation and generalized inflammation are associated with frailty among people with HIV. AIDS2025;39(2):153–161.
38.
Kirkegaard-KlitboDM, LangkildeA, MejerN, et al.Soluble Urokinase plasminogen activator receptor is a predictor of incident non-AIDS comorbidity and all-cause mortality in human immunodeficiency virus type 1 infection. J Infect Dis2017;216(7):819–823.
39.
TenorioAR, ZhengY, BoschRJ, et al.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis2014;210(8):1248–1259.
40.
BurdoTH, LoJ, AbbaraS, et al.Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis2011;204(8):1227–1236.
41.
RasmussenLJ, KnudsenA, KatzensteinTL, et al.Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: A nested case-control study. HIV Med2016;17(5):350–357.
42.
DelaneyJAC, OlsonNC, SitlaniCM, et al.Natural killer cells, gamma delta T cells and classical monocytes are associated with systolic blood pressure in the multi-ethnic study of atherosclerosis (MESA). BMC Cardiovasc Disord2021;21(1):45.
43.
SinhaA, RiveraAS, DoyleMF, et al.Association of immune cell subsets with cardiac mechanics in the Multi-Ethnic Study of Atherosclerosis. JCI Insight2021;6(13):e149193.
44.
MillerYI, ChoiSH, FangL, et al.Toll-like receptor-4 and lipoprotein accumulation in macrophages. Trends Cardiovasc Med2009;19(7):227–232.
45.
TaylorBS, So-ArmahK, TateJP, et al.HIV and obesity comorbidity increase interleukin 6 but not soluble CD14 or D-Dimer. J Acquir Immune Defic Syndr2017;75(5):500–508.
46.
ThuMS, CampbellBJ, HirankarnN, et al.Cannabis and cannabinoid-microbiome interactions in varied clinical contexts: A comprehensive systematic review. Biomed Pharmacother2025;182:117764.
47.
MorganE, ManuzakJA, BroedlowC, et al.Problematic cannabis use is associated with reduced rectal microbial species richness and diversity among a pilot sample of young sexual and gender minorities. AIDS Res Hum Retroviruses2024;40(1):1–6.
48.
ManuzakJA, GottTM, KirkwoodJS, et al.Heavy cannabis use associated with reduction in activated and inflammatory immune cell frequencies in antiretroviral therapy-treated human immunodeficiency virus-infected individuals. Clin Infect Dis2018;66(12):1872–1882.
49.
TurcotteC, BlanchetMR, LavioletteM, et al.The CB(2) receptor and its role as a regulator of inflammation. Cell Mol Life Sci2016;73(23):4449–4470.
50.
CabralGA, Griffin-ThomasL. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Rev Mol Med2009;11:e3.
51.
SuryavanshiSV, KovalchukI, KovalchukO. Cannabinoids as key regulators of inflammasome signaling: A current perspective. Front Immunol2020;11:613613.
52.
SprostonNR, AshworthJJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol2018;9:754.
53.
FredericksenRJ, HardingBN, RudermanSA, et al.Patient acceptability and usability of a self-administered electronic patient-reported outcome assessment in HIV care: Relationship with health behaviors and outcomes. AIDS Care2021;33(9):1167–1177.
54.
CostiniukCT, SaneeiZ, SalahuddinS, et al.Cannabis consumption in people living with HIV: Reasons for use, secondary effects, and opportunities for health education. Cannabis Cannabinoid Res2019;4(3):204–213.
55.
HahnAW, RudermanSA, NanceRM, et al.Cannabis use patterns among people with HIV before and after legalization. Drug Alcohol Depend Rep2024;13:100291.
56.
WilsonNL, PetersonSN, EllisRJ. Cannabis and the gut-brain axis communication in HIV infection. Cannabis Cannabinoid Res2021;6(2):92–104.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
